Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial

Schneeweiss Andreas; Moebus Volker; Tesch Hans; Hanusch Claus; Denkert Carsten; Luebbe Kristina; Huober Jens; Klare Peter; Kuemmel Sherko; Untch Michael; Kast Karin; Jackisch Christian; Thomalla Joerg; Ingold-Heppner Barbara; Blohmer Jens-Uwe; Rezai Mahdi; Frank Matthias; Engels Knut; Rhiem Kerstin; Fasching Peter Andreas; Nekljudova Valentina; von Minckwitz Gunter; Loibl Sibylle

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial

【24h】

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial

机译：激烈剂量 - 致密的Epirubicin，紫杉醇，环磷酰胺与每周紫杉醇，脂质体Doxorubicin（加上三重阴性乳腺癌中的Carboplatin）用于Neoadjuvant治疗高危早期乳腺癌（Geparocto-GBG 84）：随机期III试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) and weekly treatment with paclitaxel plus non-pegylated liposomal doxorubicin (M, Myocet (R)) with additional carboplatin (PM(Cb)) in triple-negative BC (TNBC).

机译：背景：Geparocto比较高风险早期乳腺癌两种化疗方案的疗效和安全性：用激烈剂量 - 致密的Epirubicin，紫杉醇和环磷酰胺（Iddepc）顺序治疗和与紫杉醇加上非聚乙二醇化脂质体Doxorubicin的每周治疗（ M，Myocet（R））在三重阴性BC（TNBC）中具有额外的卡铂（PM（CB））。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2019年第2019期|共12页
作者
Schneeweiss Andreas; Moebus Volker; Tesch Hans; Hanusch Claus; Denkert Carsten; Luebbe Kristina; Huober Jens; Klare Peter; Kuemmel Sherko; Untch Michael; Kast Karin; Jackisch Christian; Thomalla Joerg; Ingold-Heppner Barbara; Blohmer Jens-Uwe; Rezai Mahdi; Frank Matthias; Engels Knut; Rhiem Kerstin; Fasching Peter Andreas; Nekljudova Valentina; von Minckwitz Gunter; Loibl Sibylle;
展开▼
作者单位

Natl Ctr Tumor Dis NCT Heidelberg Germany;

Clin Frankfurt Hoechst Dept Gynaecol &

Obstet Frankfurt Germany;

Praxis Bethanien Frankfurt Germany;

Clin Red Cross Munich Germany;

Charite Berlin Germany;

Henriettenstiftung Hannover Hannover Germany;

Univ Hosp Ulm Ulm Germany;

Praxisklin Krebsheilkunde Frauen Berlin Berlin Germany;

Clin Essen Mitte Breast Ctr Essen Germany;

HELIOS Clin Berlin Buch Berlin Germany;

Univ Hosp Dresden Dresden Germany;

Sana Clin Offenbach Offenbach Germany;

Clin Haematol &

Oncol Koblenz Koblenz Germany;

Charite Berlin Germany;

Charite Berlin Germany;

Luisenkrankenhaus Dusseldorf Med Ctr Dusseldorf Germany;

Ortenau Clin Offenburg Germany;

Zentrum Pathol Zytol &

Mol Pathol Neuss Neuss Germany;

Univ Hosp Cologne Clin Ctr Familial Breast &

Ovarian Canc Cologne Germany;

Friedrich Alexander Univ Erlangen Nuremberg Comprehens Canc Ctr Erlangen EMN Univ Hosp Erlangen;

German Breast Grp Neu Isenburg Germany;

German Breast Grp Neu Isenburg Germany;

Praxis Bethanien Frankfurt Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Dose-dense; Neoadjuvant; High-risk early breast cancer; Carboplatin;

机译：剂量密集;Neoadjuvant;高风险早期乳腺癌;卡铂;

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial [J] . Schneeweiss Andreas, Moebus Volker, Tesch Hans, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：激烈剂量 - 致密的Epirubicin，紫杉醇，环磷酰胺与每周紫杉醇，脂质体Doxorubicin（加上三重阴性乳腺癌中的Carboplatin）用于Neoadjuvant治疗高危早期乳腺癌（Geparocto-GBG 84）：随机期III试验
3. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. [J] . Untch M, von Minckwitz G, Konecny GE, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第9期

机译：PREPARE试验：一项III期随机试验，比较了在原发性乳腺癌中使用表柔比星，紫杉醇和CMF与标准剂量的表柔比星-环磷酰胺与紫杉醇联合或不联合使用达比泊汀阿尔法的术前，剂量密集，剂量增强化疗的结果预后。
4. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/- darbepoetin alfa in primary breast cancer--results at the time of surgery. [J] . Untch M, Fasching PA, Konecny GE, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第9期

机译：PREPARE试验：一项III期随机试验，比较了在原发性乳腺癌中使用表柔比星，紫杉醇和CMF与标准剂量的表柔比星/环磷酰胺再用紫杉醇+/-达比泊汀α进行的术前，剂量密集，剂量增强化疗的比较，结果手术时间。
5. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
6. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
7. Cyclophosphamide Epirubicin and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer [O] . Margot Burnell, Mark N. Levine, Judith-Anne W. Chapman, -1

机译：淋巴结阳性或高风险淋巴结阴性乳腺癌中环磷酰胺表柔比星和氟尿嘧啶与剂量密集的表柔比星和环磷酰胺继之以紫杉醇对阿霉素和环磷酰胺再继之为紫杉醇。
8. Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer [O] . Burnell, Margot, Levine, Mark N., Chapman, Judith-Anne W., 2010

机译：淋巴结阳性或高风险淋巴结阴性乳腺癌中环磷酰胺，表柔比星和氟尿嘧啶与剂量密集的表柔比星和环磷酰胺，继之以紫杉醇对阿霉素和环磷酰胺，再继之为紫杉醇。

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial

摘要

著录项

相似文献

相关主题

期刊订阅